Protein metabolism
Muscle wasting in the patient with cancer is clear evidence of an altered protein metabolism. This subject has been reviewed recently by Schersten et al. (1982) . Though most of the studies have been done in experimental animals, the few that have been done in patients appear to confirm the experimental observations. The conclusions, as summarized in the review, are that cancer results in increased whole body protein turnover, an increased rate of protein synthesis in the liver, but a decreased rate of synthesis in skeletal muscle with a simultaneous increase in net degradation of skeletal muscle protein. In the study of protein metabolism, as with every aspect of the nutrition of the cancer patient, much more attention needs to be directed to understanding the importance of tumour specificity. The energy costs of protein synthesis in the overall energy balance of the body seem to account only for about 20% of the negative energy balance of the tumour host. What accounts for the remainder of the deficit in energy balance?
When considering the desirability or efficiency of nutritional support in the cancer patient, it is most important to know when such support is likely to reverse the alterations in protein metabolism. Present evidence seems to indicate that these alterations can only partly be reversed.
Hypoalbuminaemia is common in patients with cancer and may be the result of decreased synthesis, increased metabolism, increased plasma volume or the passage of protein-rich fluid into the gut: protein-losing enteropathy (Waldmann et al. 1974) . It is clear that without the knowledge of the reasons for low plasma albumin concentrations, it is impossible to use the measurement as an index of nutritional status (Moore et al. 1982) . ' Accepted 17 November 1983 /. 1984 The Royal Society of Medicine 0 1 41-0768/84/040309-07/$O 1.00/0 However, knowledge of the disturbances in albumin metabolism could be of help in the management of the cancer patient (Raines et al. 1982) . Albumin plays an important role in the transport of drugs and specifically of chemotherapeutic agents. Raines et al. (1982) emphasized the importance of an understanding of the effects of nutrition on albumin metabolism because of its critical importance in relation to drug transport and actions.
Fat metabolism
Depletion of body fat is a characteristic feature of cancer cachexia. Studies suggesting that a rise in plasma free fatty acids (FFA) could be correlated with clinical activity of the tumour (Mueller & Watkin 1961) have not been confirmed (Holroyde et al. 1975 , Schein et al. 1979 . FFA oxidation has been reported to be reduced less by glucose in cancer patients than in controls (Waterhouse & Kemperman 1971) and this was interpreted as evidence of continuous intracellular oxidation of FFA after glucose loading. This suggests that the patient with metastatic cancer retains a fasting state of oxidative metabolism in the fed condition. Thus, there is failure of normal homeostatic mechanisms, possibly due to insulin insensitivity (Lundholm et al. 1978) . Further information in support of these changes in the host's metabolism has been obtained from measurements of the concentrations of various metabolites in the liver. The presence of a C3H mammary tumour weighing only 16 mg in mice caused a highly significant fall in the concentration of acetyl Co-A with a rise in that of citrate (McAllister et al. 1976) . Curative resections of the C3H tumour caused a return of acetyl Co-A levels to the normal range (Calman et al. 1977 ).
Effects of cancer on specific nutrients
Numerous studies have been made of the blood and tissue levels of various minerals and vitamins in patients with cancers at different sites (see in the hope that they will yield information which could be used to modify the environment of cancer cells and retard their growth. The results of many of these studies are difficult to interpret, and studies of this sort are of little value unless designed to answer a specific question and the samples taken under tightly controlled conditions.
Cell-mediated immunity
Depressed cell-mediated immunity (CMI) has been reported in undernourished patients with cancer of the oesophagus (Haffejee et al. 1978 , Haffejee & Angorn 1979 , head and neck (Brookes & Clifford 1981) and at various sites in the gastrointestinal tract (Burke et al. 1983 ). In the study by Burke and colleagues, the CMI in patients with different stages of cancer spread and undernutrition was compared with that in a group of patients with nonmalignant disease but different degrees of undernutrition. The results suggested that the degree of depression of CMI was related to the degree of undernutrition irrespective of disease or stage. Thus, undernutrition is the overriding factor and improvements in nutritional status would be expected to lead to an increase in CMI in patients with gastrointestinal cancer because the phenomenon is not cancer-specific.
Other causes of weight loss
As well as the metabolic disturbances outlined above, weight loss in the cancer patient may be caused by a reduced energy intake due to anatomical interference with food intake, disturbed psychological condition and aberrations of taste. The contribution of these factors will differ in different individuals. In patients with cancer of the oral cavity, oesophagus or stomach, there is obvious physical interference with food ingestion, swallowing or appetite. It is important to assess the role of psychological factors in individual patients. Feelings of worthlessness, loss of self-esteem, pessimism, guilt and suicidal ideas (Holland et al. 1977 ) are common. The patient's own beliefs and attitude to his disease and its treatment are important factors in causing anorexia (Schmale 1979) . If left to themselves, patients may be unable to overcome the sense of hopelessness which can lead to an adaptive biological reaction called 'conservation-withdrawal'.
Taste Many patients with cancer complain of disturbances in the sense of taste. These disturbances may be quantified by the measurement of taste threshold using a technique established in patients with adrenal cortical insufficiency (Henkin et al. 1963 ). The threshold for sweetness is determined with solutions of sucrose, that for bitterness with urea, that for saltiness with sodium chloride solution and that for sourness with hydrochloric acid. De Wys (1978) , in summarizing the results of previous investigations of taste in cancer patients, pointed out that the incidence of abnormalities is directly proportional to the tumour burden, rarely being found in subjects with limited tumour growth, and most common in those in whom tumour growth is extensive. Moreover, there seems to be an interrelationship with calorie intake because, if this can be increased, the taste disturbances tend to decrease. De Wys stressed the importance of a knowledge of taste aberrations in the dietetic management of cancer patients. Thus, patients with a reduced bitter threshold find beef and pork less desirable, poultry and fish intermediate, but cheese and eggs pleasurable. An elevated sweet threshold can be counteracted by giving increased emphasis to seasoning.
Disturbance of certain tastes may occur more frequently in patients with tumours at specific sites. Thus, patients with lung cancer prior to radio-or chemotherapy had a diminished taste recognition threshold for sour but no abnormalities for bitter, sweet and salt thresholds (Williams et al. 1978 ). On the other hand, patients with gastrointestinal cancer have been reported to recognize bitter taste at a lower threshold than control subjects (Hall et al. 1980) . A significant increase in the recognition threshold for bitter has been reported in patients with metastatic carcinomas and for sour in patients with squamous cell carcinomas, and a significant decrease for sour in patients with breast cancer (Settle et al. 1979) .
Deficiencies of certain nutrientszinc, vitamins of the B complex and vitamin Aare a cause of taste disturbances (Schiffman 1983 ), but their role in cancer patients seems not to have been studied.
Differences in thresholds for certain tastes in the cancer patient account for differences in the acceptability of prepared feeds used as food supplements (Gallagher & Tweedle 1981) . In the feeding of cancer patients, taste and acceptability of food may be more important than composition.
The possibility that cancer anorexia may be caused by learned food aversions has been examined in rats (Bernstein & Sigmundi 1980) . Rats given implants of a polyoma virusinduced sarcoma developed anorexia and cachexia. The decline in food intake which accompanied tumour growth was accompanied by the development of aversion to the specific diet consumed during tumour growth. An intermediate elevation in food intake occurred when a novel diet was introduced. The same workers have reported that children receiving cancer chemotherapy developed aversions to familiar foods in their usual diet when these foods were consumed prior to drug treatments (Bernstein et al. 1982 ). These aversions were evidently learned due to the association of these foods with the symptoms of drug treatment. Many of these aversions proved to be persistent, lasting for several months. These authors suggested that a novel taste, presented in association with the antitumour drugs, might act as an interference stimulus and prevent or attenuate aversions to normal dietary components.
Feeding the cancer patient A critical question in our consideration of the feeding of the cancer patient is to what extent it may be expected that all aspects of the deranged metabolism characteristic of cancer cachexia may be reversed. This should be the long-term goal, but that is not to say that we should ignore the possibility of short-term benefits of an adjunctive nature if nutritional support is seen as part of the total management of the patient. Careful assessment of individual patients is necessary in order to understand not only the needs of that patient but also the benefit likely to accrue and, thus, the justification for a particular means of nutritional support. The assessment of benefit is made more difficult by the fact that the total benefit is only partly physical. Improvement in well-being and psychological condition is of at least equal importance. In a study of leukaemia patients, the patient's own psychological attitudes to his disease and its treatment played an important role in determining food intake (E Janes, R Powles & J Dickerson, in preparation).
Food is normally taken orally. However, the anorectic cancer patient is most unlikely to consume sufficient food to meet his requirements, no matter how it is presented. The gastrointestinal tract should always be used when possible, and with a fine-bore tube complete feeds can be introduced into the stomach or upper small intestine. Enteral feeding has a distinct metabolic advantage compared with parenteral feeding. It is also very much cheaper, particularly as complete feeds can be made up by a dietician.
Enteral feeding is often not possible in those patients most in need of intensive nutritional support, and considerable attention has focused on the role of total parenteral nutrition (TPN). Studies by Solassol et al. (1972) and Copeland et al. (1974) suggested that TPN was useful in putting cancer patients into a satisfactory condition for specific antitumour therapy. TPN constitutes an 'aggressive' method of feeding, for the amounts of nutrients given are in no way determined by the patient. It is therefore not unreasonable that concern should be felt about the effects of TPN on tumour growth. This concern seemed justified because improving the nutritional status of tumour-bearing animals stimulates tumour growth (Moore & Tittle 1973 , Ross & Bras 1973 and Cameron & Pavlat (1976) showed that TPN stimulated growth of transplanted hepatoma in the rat. Copeland et al. (1974) concluded that there was no scientific evidence to suggest that TPN stimulated the growth of human cancers. It could be argued that even if such an effect did occur, it might do no harm provided that effective antitumour therapy was given at the same time.
Early reports from the USA (Dudrick et al. 1969 , Rush et al. 1970 suggested that TPN improved the general condition and mood of cancer patients and was accompanied by a positive nitrogen balance. Copeland et al. (1975b) reported benefits with respect to wound healing and recovery in patients with head and neck cancer in whom surgery would not have been possible without TPN. A beneficial effect on the healing of postoperative fistulas in cancer patients given TPN postoperatively was reported by Sudjian (1975) . The same workers had compared the effectiveness of parenteral and enteral feeding postoperatively in patients with oropharyngeal cancer: of particular note was the finding that more (92%) of the patients who received TPN compared with those who received enteral feeding (55%) had primary healing of their wounds (A Sudjian & A Wretlind, unpublished observations).
Changes in body weight are unreliable as an index of the nutritional efficacy of feeding programmes. The surgeon is often faced with a malnourished cancer patient and has to decide whether to provide nutritional support before as well as after surgery. Nitrogen balance studies in patients with obstructive carcinoma of the oesophagus (Moghissi et al. 1977) showed that patients given a high energy and nitrogen regimen before and after surgery were in positive nitrogen balance and had a satisfactory postoperative progress. This was in contrast to the findings of negative nitrogen balance and unsatisfactory progress in a control group given glucose and saline until resumption of oral feeding.
In a larger study, Muller et al. (1982) reported on the effects of 10 days preoperative TPN in patients with gastrointestinal carcinoma. The results in 66 patients treated in this way were compared with those in a matched series of 59 control patients who received the normal hospital diet. The authors reported a significantly lower incidence of major complications and mortality in the TPN-treated group. Taken at face value the results were impressive, since this would seem to be the only study to demonstrate an improvement in case-fatality rate. However, the way in which the study was done has been severely criticized (Koretz 1983) and it seems that the value of preoperative TPN in patients with gastrointestinal cancer is still open to question.
Radiation to the head and neck results in reduced salivary secretion and changes in taste and smell, a condition known as 'mouthblindness' (MacCarthy-Leventhal, 1959) . Oral ulceration, cheilosis, glossitis and pharyngitis may result from chemotherapy regimens. Consequent reductions in food intake may be prevented by the use of suitably-flavoured food supplements, or in severe cases by nasogastric feeding.
Radiation enteritis with consequent diarrhoea of varying severity may be a serious complication of pelvic irradiation. Because of the late presentation of this problem in some patients, the role of nutrition in its prevention seems to have received little attention. It may be that enteral feeding during the period of treatment (Bounous et al. 1975 ) would afford some protection.
Discomfort caused by the effects of radiation or chemotherapy on the gastrointestinal tract can be avoided by using an intravenous route. However, the long-term benefit of TPN given before and during radiotherapy depends on the response of the tumour to radiation (Copeland et al. 1977b) . In 20 patients who responded to treatment, these workers reported a mean weight gain of 5.9 kg which in most patients was maintained after TPN was stopped, whereas in patients whose tumours did not respond the mean weight gain was only 2.2 kg and these patients lost weight immediately after TPN was stopped.
Recently attention has been directed towards the effects of antitumour drugs on specific nutrients. Some drugs, such as methotrexate, rely on interaction with a specific nutrient for their therapeutic value. Others may interact with nutrients and produce adverse effects due to nutrient deficiencies. Thus, 5-fluorouracil (5-FU), either alone or in combination with other drugs, produces biochemical evidence of thiamine deficiency (Aksoy et al. 1980 ) which can be corrected by giving large doses of this vitamin. It has been suggested that 5-FU interferes with the phosphorylation of thiamine. It is tempting to give thiamine routinely to patients receiving 5-FU, but it needs first to be established that thiamine will not stimulate the growth of tumour cells or, more importantly, decrease the antitumour effect of the drug. A longitudinal study in patients with metastatic testicular cancer (Atukorala et al. 1983 ) treated with Samuels' regimen (Samuels et al. 1976 ) of bleomycin and vinblastine has shown decreases in status with respect to a number of vitamins during treatment, with partial recovery between courses.
A malnourished cancer patient is not a good candidate for chemotherapy. Enteral support even with a nasogastric tube may be difficult, particularly during courses of active treatment. Attention has therefore been centred on the possible beneficial role of TPN. Copeland et al.
(1 975a, 1 977a) reported a positive correlation between nutritional status and tumour response. 5-fluorouracil is better tolerated and higher doses can be given to patients receiving TPN (Schwartz et al. 1971 ). However, Samuels et al. (1981) reported no difference in response of teratomas in patients treated with their regimen whether patients were given TPN or not, despite weight gain in the TPN-treated group and weight loss in the control group.
It is tempting for the oncologist to see in TPN an important adjunct to antitumour treatment. However, claims made for the beneficial effects of TPN have recently been examined more critically. As indicated earlier, the really important question is the extent to which this form of nutritional support, often the only means available, will reverse the metabolic effects of the disease. Brennan (1981) has reviewed the experience with 19 randomized studies including approximately 700 patients. In none of these studies did TPN impart a clearly definable benefit. Detailed metabolic studies in patients with metastatic disease (Nixon et al. 1981) have shown that there is a partial block in repletion of lean body mass and that the metabolic effects of the disease are only partially reversible.
The role of nutritional support in children receiving antitumour therapy has received particular attention. It has been suggested that patients with Wilms' tumours will benefit from early and continued provision of adequate nutrition such as that provided by TPN (Rickard et al. 1982) . Cyclic TPN has been reported (Reed et al. 1983 ) to be a useful practical approach to the maintenance of nutrition during intensive antitumour therapy in patients having bone marrow transplants.
Conclusion
Malnutrition is common in the cancer patient. The causes of anorexia in these patients are complex, as too are the metabolic changes induced by tumours. There is absolutely no need for the cancer patient to suffer from any form of malnutrition. However, the results of many studies in patients receiving antitumour therapy provide little support for the general provision of aggressive nutritional support. There is no doubt that such support is essential in some patients in order to enable them to survive the effects of antitumour therapy. TPN is, however, expensive and its administration not without risk.
The need for nutritional support should be considered in the light of the patient's condition and carefully planned along with specific antitumour therapy. Attention should be given to immediate requirement and how it will alter during therapy and recovery. The means of administration most appropriate to the patient and the benefits likely to be achieved are also major considerations. Feeding is an important aspect of total patient care, and the need for it in the cancer patient extends from the hospital into the home and may be required as long as useful life remains.
